CORRECTION

Journal Correction

The October 20, 2011, article by Pawlik et al, entitled, “Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma” (J Clin Oncol 29:3960-3967, 2011), contained errors.

In Table 2, the data in most of the rows were mistakenly shifted left one or more columns. The corrected table is reprinted below in its entirety.

Journal of Clinical Oncology apologizes to the authors and readers for the mistakes. The online version has been corrected in departure from the print.

DOI: 10.1200/JCO.2011.40.2818

Table 2. Treatment Toxicities Stratified by Cycle

Toxicity	Grade															
	Week 1, Cycle One (sorafenib only; n = 35)								Cycle One (n = 33)							
	Any		1 to 2		3 to 4				Any		1 to 2		3 to 4		Any	
	No.	%	No.	%	No.	%			No.	%	No.	%	No.	%	No.	%
Any	32	91	30	86	9	26			33	100	33	100	30	91	28	100
Blood/bone marrow suppression																
Anemia									12	36	11	33	1	3	8	29
Leukocytopenia									6	18	6	18			5	18
Lymphopenia									14	42	9	27	5	15	10	37
Neutropenia									1	3	1	3			1	4
Thrombocytopenia	1	3	1	3					7	21	7	19			5	18
Cardiac events																
Arrhythmia									3	9	3	9			1	4
Hypertension	4	12	4	12					4	12	2	126	2	6	1	4
Cardiovascular system																
Edema									9	27	8	24	1	3	1	4
Coagulation																
Elevated INR									12	36	12	36			8	29
Constitutional symptoms																
Fatigue	18	52	16	46	2	6			31	94	19	57	12	36	22	79
Fever	4	12	4	12					16	48	16	48			4	14
Insomnia	1	3	1	3					10	30	10	30			4	15
Night sweats	2	6	2	6					9	27	9	27			3	11
Weight loss									1	3	1	3			3	11
Dermatologic events																
Alopecia	1	3	1	3					14	42	14	42			7	25
Dry skin	1	3	1	3					2	6	2	6			3	11
HSFR	11	32	8	23	3	9			16	48	10	30	6	18	11	39
Mucositis	2	6	2	6					5	15	5	15			1	4
Pruritis	2	6	2	6					6	18	6	18			2	8
Rash	7	20	6	17	1	3			16	48	13	39	3	9	1	4
GI events																
Ascites									3	9	3	9				
Anorexia	4	11	4	11					22	67	22	66			9	32
Constipation	4	11	4	11					15	46	15	45			7	25
Diarrhea	3	9	3	9					10	30	10	30			6	21
Dry mouth	3	9	3	9					3	9	3	9			1	4
Early satiety	1	3	1	3					1	3	1	3			1	4
Gastritis/heartburn/indigestion	3	9	3	9					4	12	4	12			1	4
Nausea	4	11	4	11					11	33	11	33			5	18
Taste alteration									4	12	4	12			2	8
Vomiting	2	6	2	6					6	18	6	18			1	4
Hemorrhage/bleeding	1	3	1	3					1	3	1	3			2	7
Hepatic/pancreatic function																
Elevated ALT	1	3	1	3					18	55	8	24	10	30	7	26
Elevated AST									16	48	8	24	8	24	9	33
Elevated AP									14	42	12	36	2	6	15	43
Elevated amylase									6	18	6	18			3	11
Elevated lipase	1	3			1	3			11	33	7	21	4	12	5	18
Hyperbilirubinemia	1	3	1	3					21	64	14	42	7	21	9	32
Hypoalbuminemia									19	58	17	51	2	6	11	40
Hypophosphatemia									10	30	10	30			2	7
Infection									4	12	3	9	1	3	2	8
Liver abscess															1	4
Musculoskeletal																
Cramping	2	6	2	6					3	9	3	9			2	7
Skeletal pain	2	6	2	6					6	18	5	15	1	3	2	8

(continued on following page)

Table 2. Treatment Toxicities Stratified by Cycle (continued)

Toxicity	Grade																			
	Week 1, Cycle One (sorafenib only; n = 35)								Cycle One (n = 33)						Cycles Two and Beyond (n = 28)					
	Any		1 to 2		3 to 4		Any		1 to 2		3 to 4		Any		1 to 2		3 to 4			
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%		
Neurologic symptoms/events																				
Ataxia	1	3	1	3																
Cognitive impairment	1	3	1	3			1	3	1	3										
Dizziness	1	3	1	3			2	6	2	6										
Headache	3	9	3	9			4	12	4	12										
Encephalopathy	1	3			1	3	2	6			2	6	1	4			1	4		
Pain																				
Abdominal nonspecific	2	6	2	6			9	27	4	12	5	15	11	50	5	18	6	24		
Chest							3	15	2	6	1	3	1	4	1	4				
Epigastric							1	3	1	3			2	7	2	7				
Right upper quadrant	5	17	4	14	1	3	15	45	11	33	4	12	4	15	3	11	1	4		
Other	4	12	4	12			9	27	8	24	1	3								
Pulmonary																				
Cough	1	3	1	3			5	15	5	15			1	4	1	4				
Dyspnea							2	6	1	3	1	3	3	11	3	11				
Dyspnea on exertion							3	9	3	9										
Pulmonary embolus/coagulopathy							1	3			1	3	3	11	3	11				
Raspy voice/sore	7	20	7	20			10	30	10	30										
Renal																				
Elevated creatinine							1	3	1	3			4	14	4	14				
Acute renal failure							2	6	2	6										
Urinary frequency/incontinence	2	6	2	6			3	9	3	9										
Sexual																				
Decreased libido	1	3	1	3			2	6	2	6										

Abbreviations: AP, activator protein; HFSR, hand-foot-skin reaction; INR, international normalized ratio.